Clinical Trial

Prostate Cancer Imaging

Study Description

PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

The purpose of the study is to provide pilot data on the clinical situations in which ordering a 18F-DCFPyL positron emission tomography/computed tomography (PET/CT) was thought to be clinically useful, and to document how the results of the 18F-DCFPyL PET/CT affected patient management. The results of this study could then serve as a guide to help OHIP to consider these scenarios when deciding the precise indications for funded 18F-DCFPyL PET/CT scans in the future. In this study the investigators will image subjects with prostate cancer using 18F-DCFPyL PET/CT and record how the result of the study affected patient management.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Diagnostic Test - 18F-DCFPyL PET/CT

A bolus of less than or equal to 9 mCi (333 MBq) of 18F-DCFPyL will be injected IV by slow IV push. After administration of the 18F-DCFPyL the line will be flushed with saline (0.9% w/v). Subjects should be encouraged to drink up to 500 mL of water shortly after the administration of 18F-DCFPyL. At 60-minutes (± 10 minutes) after administration of 18F-DCFPyL, the PET/CT scan will be acquired with the subject in the supine position and the FOV including the mid-thighs to skull base.

Additional Information

Official Study Title

PSMA-based 18F-DCFPyL PET/CT: Evaluating Its Application in Real Life

Clinical Trial ID

NCT03609736

ParticipAid ID

eZ64we